In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.
The MICs of six fluoroquinolones as well as minocycline and cefotaxime for 46 clinical isolates of Vibrio vulnificus were determined by the agar dilution method. All the drugs tested had good activities against all isolates, with the MICs at which 90% of the isolates tested were inhibited (MIC(90)s) by five of the fluoroquinolones ranging between 0.03 and 0.06 micro g/ml. The MIC(90) of lomefloxacin, on the other hand, was 0.12 micro g/ml. Time-kill studies were conducted with these agents and a clinical strain of V. vulnificus, VV5823. When approximately 5 x 10(5) CFU of V. vulnificus/ml was incubated with any one of the above-mentioned six fluoroquinolones at concentrations of two times the MIC, there was an inhibitory effect on V. vulnificus that persisted for more than 48 h with no noted regrowth. The efficacies of the fluoroquinolones were further evaluated in vivo in the mouse model of experimental V. vulnificus infection and compared to the efficacy of a combination therapy using cefotaxime plus minocycline. With an inoculum of 1.5 x 10(7) CFU, 28 (87.5%) of 32 mice in the cefotaxime-minocycline-treated group survived and 29 (91%) of the 32 mice in the moxifloxacin-treated group survived while none of the 32 mice in the control group did. With an inoculum of 3.5 x 10(7) CFU, the difference in survival rates among groups of 15 mice treated with levofloxacin (13 of 15), moxifloxacin (10 of 15), gatifloxacin (10 of 15), sparfloxacin (11 of 15), ciprofloxacin (12 of 15), or lomefloxacin (10 of 15) was not statistically significant while none of the 15 mice treated with saline survived. We concluded that the newer fluoroquinolones as single agents are as effective as the cefotaxime-minocycline combination in inhibiting V. vulnificus both in vitro and in vivo.
Tang
Hung-Jen
HJ
Departments of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Chang
Ming-Chung
MC
Ko
Wen-Chien
WC
Huang
Kun-Yen
KY
Lee
Chih-Lung
CL
Chuang
Yin-Ching
YC
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002439:Cefotaxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D015169:Colony Count, Microbial; D024841:Fluoroquinolones; D051379:Mice; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000494:pharmacology; D016019:Survival Analysis; D013997:Time Factors; D014735:Vibrio Infections / Q000188:drug therapy / Q000382:microbiology; D041261:Vibrio vulnificus / Q000187:drug effects* / Q000254:growth & development
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D008911:Minocycline; D002439:Cefotaxime